Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

Mark Basik ,C W Wilson ,Shahzeb Hassan ,K I Pritchard ,L E Shepherd ,J-Aw Chapman ,Adriana Aguilar‐Mahecha ,Kaushar Jahan ,Han Liang ,Michaël Pollak

doi:10.1200/jco.2010.28.15_suppl.551

Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

Mark Basik , C W Wilson + Show 8 more

https://doi.org/10.1200/jco.2010.28.15_suppl.551

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2010

#Stromal Cell Derived-factor 1 #NCIC CTG MA + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

551 Background: Stromal cell derived-factor 1 (SDF-1) is a chemokine implicated in various aspects of breast tumor growth and metastasis. Blood SDF-1 levels have a significant prognostic value in p...

Full Text

Published version (

Free)

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

R Discovery Prime

R Discovery Prime

Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

Abstract

Talk to us

Similar Papers

More From: Journal of Clinical Oncology

Lead the way for us

Editage

Paperpal

R Discovery

Mind the Graph

R Discovery Prime

R Discovery Prime

Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

Abstract

Talk to us

Similar Papers

More From: Journal of Clinical Oncology